Phase 2, Phase 3 Recruiting Academic/Other
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
Sponsor: NRG Oncology
NCT ID: NCT05174169
Sites in Georgia: - Phoebe Putney Memorial Hospital — Albany, Georgia
- University Cancer and Blood Center LLC — Athens, Georgia
- Piedmont Hospital — Atlanta, Georgia
- Northside Hospital — Atlanta, Georgia
- Northside Hospital - Duluth — Duluth, Georgia
Phase 3 Recruiting Network
This phase III trial evaluates whether a web-based intervention called Current Together after Cancer (CTAC) works to increase the number of patients with surgically removed (resected) colorectal cancer who receive surveillance care that al…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT07018869
Sites in Georgia: - Augusta University Medical Center — Augusta, Georgia
- Northeast Georgia Medical Center Braselton — Braselton, Georgia
- Northeast Georgia Medical Center-Gainesville — Gainesville, Georgia
- The Longstreet Clinic - Gainesville — Gainesville, Georgia
- Memorial Health University Medical Center — Savannah, Georgia
Phase 3 Recruiting Industry
The purpose of this study is to learn more about a new medicine called PF-08634404, and how well it works in people with cancer of the colon or rectum (CRC)). The goal is to understand if the new study medicine, combined with chemotherapy …
Sponsor: Pfizer
NCT ID: NCT07222800
Sites in Georgia: - University Cancer & Blood Center, LLC — Athens, Georgia
Phase 3 Recruiting Industry
This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participa…
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT05253651
Sites in Georgia: - Emory University Hospital Midtown — Atlanta, Georgia
- Emory University Hospital — Atlanta, Georgia
- Winship Cancer Institute — Atlanta, Georgia
- Emory Saint Joseph's Hospital — Atlanta, Georgia
Phase 3 Recruiting Industry
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) versus Bevacizumab in Combination with FOLFOX for the First-line Tr…
Sponsor: Summit Therapeutics
NCT ID: NCT07228832
Sites in Georgia: - Clinical Study Site — Atlanta, Georgia
- Clinical Study Site — Atlanta, Georgia
- Clinical Study Site — Newnan, Georgia
Phase 3 Recruiting Network
This study is being done to answer the following questions: Is the chance of rectal cancer responding the same if chemotherapy alone is given before limited surgery compared to chemotherapy and radiation therapy given together before limit…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06205485
Sites in Georgia: - Emory University Hospital Midtown — Atlanta, Georgia
- Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
- Emory Saint Joseph's Hospital — Atlanta, Georgia
Phase 3 Recruiting Industry
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fl…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06750094
Sites in Georgia: - University Cancer And Blood Center LLC — Athens, Georgia
- Grady Memorial Hospital — Atlanta, Georgia
- Piedmont Cancer Institute — Atlanta, Georgia
- Winship Cancer Institute Emory University — Atlanta, Georgia
Phase 3 Recruiting Network
This phase III trial compares hepatic arterial infusion (HAI) (pump chemotherapy) in addition to standard of care chemotherapy versus standard of care chemotherapy alone in treating patients with colorectal cancer that has spread to the li…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT05863195
Sites in Georgia: - Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
- Emory Saint Joseph's Hospital — Atlanta, Georgia
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untreated, unresectable, or metastatic color…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07221357
Sites in Georgia: - Local Institution - 0326 — Atlanta, Georgia
- Northside Hospital — Atlanta, Georgia
- Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital — Marietta, Georgia
Phase 3 Recruiting Industry
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess the adverse events and change in disease activity of telisotuzumab adizutecan plus bevacizumab compared to standard…
Sponsor: AbbVie
NCT ID: NCT07525206
Sites in Georgia: - City Of Hope - Atlanta /ID# 280017 — Newnan, Georgia
Phase 1, Phase 2 Recruiting Industry
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in Georgia: - University Cancer and Blood Center — Athens, Georgia
- Local Institution - 2134 — Columbus, Georgia
Phase 2 Recruiting Industry
This is a randomized, double-blind, placebo-controlled basket trial evaluating mifomelatide (TCMCB07) administered daily by subcutaneous (SC) injection in up to 120 patients. Patients will be enrolled into two cohorts 1) patients with newl…
Sponsor: Endevica Bio
NCT ID: NCT06937177
Sites in Georgia: - Piedmont Healthcare Inc. — Atlanta, Georgia
Phase 1, Phase 2 Recruiting Industry
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT05379985
Sites in Georgia: - Piedmont Healthcare — Atlanta, Georgia
Phase 1, Phase 2 Recruiting Industry
This study will help find the most suitable dose of ASP546C in people with gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other specific solid tumors. GEJ is where the food pipe (esophagus) joins the stomach…
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT07488676
Sites in Georgia: - Winship Cancer Institute at Emory University — Atlanta, Georgia
Phase 1, Phase 2 Recruiting Industry
Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the bo…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06428409
Sites in Georgia: - Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0303) — Marietta, Georgia
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial studies the side effects and best dose of pidnarulex when given together with cemiplimab and to see how well it works in treating patients with microsatellite stable (MSS) colorectal cancer (CRC) that does not respond…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07147231
Sites in Georgia: - Emory University Hospital Midtown — Atlanta, Georgia
- Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
- Emory Saint Joseph's Hospital — Atlanta, Georgia
Phase 2 Recruiting Academic/Other
This phase II trial tests how well immunotherapy (toripalimab) works for reducing the risk of cancer recurrence after surgery in patients with mismatch repair deficient stage IIB, IIC, or III colon cancer.
Sponsor: Emory University
NCT ID: NCT07140679
Sites in Georgia: - Emory Decatur Hospital — Atlanta, Georgia
- Emory University Hospital Midtown — Atlanta, Georgia
- Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
- Emory Saint Joseph's Hospital — Atlanta, Georgia
- Emory Johns Creek Hospital — Johns Creek, Georgia
Phase 1 Recruiting Industry
The main purpose of this study is to evaluate the safety and preliminary efficacy of CHS-114 in combination with toripalimab and/or other standard of care (SOC) compound(s) in participants with advanced or metastatic solid tumors.
Sponsor: Coherus Oncology, Inc.
NCT ID: NCT06657144
Sites in Georgia: - Winship Cancer Center - Emory University — Atlanta, Georgia
Phase 1 Recruiting Industry
This is a first-in-human, Phase I, open-label, multicenter, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of VVD-133214 monotherapy, a…
Sponsor: Vividion Therapeutics, Inc.
NCT ID: NCT06004245
Sites in Georgia: - Emory University School of Medicine — Atlanta, Georgia
Phase 1 Recruiting Industry
The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AMG 410 when administered alone or in combination with other agents in participants…
Sponsor: Amgen
NCT ID: NCT07094113
Sites in Georgia: - Emory University — Atlanta, Georgia
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Georgia: - Northeast Georgia Medical Center Braselton — Braselton, Georgia
- Atlanta VA Medical Center — Decatur, Georgia
- Northeast Georgia Medical Center-Gainesville — Gainesville, Georgia
- The Longstreet Clinic - Gainesville — Gainesville, Georgia
- Low Country Cancer Care — Savannah, Georgia
Recruiting Academic/Other
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Georgia: - Northside Hospital — Atlanta, Georgia
- John B Amos Cancer Center — Columbus, Georgia
- Northside Hospital - Duluth — Duluth, Georgia
- Liberty County Cancer Care — Hinesville, Georgia
- Regional Cancer Care - Jesup — Jesup, Georgia
NA Recruiting Academic/Other
This clinical trial is being done to learn whether using the proactive, graduated dose modification algorithm for leucovorin, 5-fluorouracil (5-FU), and oxaliplatin (FOLFOX) (PAGODA) algorithm to guide chemotherapy dosing for the FOLFOX re…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07283939
Sites in Georgia: - Northside Hospital — Atlanta, Georgia
- Tift Regional Medical Center — Tifton, Georgia
Recruiting Academic/Other
This study will examine the association between low muscle mass (myopenia) at diagnosis and chemotherapy toxicity in older adults with newly diagnosed advanced colorectal cancer.
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT03998202
Sites in Georgia: - John B Amos Cancer Center — Columbus, Georgia
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Georgia: - Massive Bio SYNERGY-AI site — Atlanta, Georgia
- Massive Bio SYNERGY-AI site — Savannah, Georgia